الصفحة الرئيسية>>Signaling Pathways>> Others>>Tiopinac (RS 40974)

Tiopinac (RS 40974)

رقم الكتالوجGC31821

تيوبيناك (RS 40974) (RS 40974) ، ديبنثيبين ، هو عامل فعال عن طريق الفم ومضاد للالتهابات ومضاد للحرارة.

Products are for research use only. Not for human use. We do not sell to patients.

Tiopinac (RS 40974) التركيب الكيميائي

Cas No.: 61220-69-7

الحجم السعر المخزون الكميّة
1mg
184٫00
متوفر
5mg
368٫00
متوفر
10mg
625٫00
متوفر
20mg
1103٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Tiopinac is a highly potent anti-inflammatory, analgesic and anti-pyretic agent.

Tiopinac (0.03-110 mg/kg) has 40 times the antiphlogistic potency of phenylbutazone. The dose required to reduce paw swelling by 30% is approximately 0.5 mg/kg. Tiopinac does not elicit overt side effects at the 20 mg/kg/day dose. Tiopinac causes a dose-related reversal of the decreases body weight caused by the adjuvant disease, the weight of those rats receiving 0.135 and 0.4 mg/kg/day being significantly greater than that of the positive controls. Tiopinac (0.3-30 mg/kg) is highly potent in inhibiting the pain evoked in the yeastinflamed hind paw of the rat[1].

[1]. Rooks WH 2nd, et al. The anti-inflammatory and analgesic profile of 6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-acetic acid (tiopinac). Agents Actions. 1980 Jun;10(3):266-73.

مراجعات

Review for Tiopinac (RS 40974)

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tiopinac (RS 40974)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.